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The hCRHtest in patients with central adrenal insufficiency 
 
In patients with central adrenal insufficiency (AI), a hCRHtest could be used to distinguish hypothalamic from 
pituitary disease1, or to suggest a very early phase of Addison's disease in patients with autoantibodies2. A 
good diagnostic accuracy has been reported in patients with hypopituitarism3, but its sensitivity is lower than 
that of the insulin tolerance test4. The role of hCRHtest in AI is consequently still a matter of debate5,6. 
Central AI was suspected in patients with known pituitary-hypothalamic disease (neoplastic lesion, brain 
surgery or radiotherapy, traumatic or vascular brain injury, or after glucocorticoid withdrawal), and signs or 
symptoms of AI (hyponatremia, fatigue, hypoglycemia). AI was diagnosed if basal morning serum cortisol 
was <83 nmol/L, or peak ACTH in the low-dose short synacthen test (LDSST, 1μg) was <500 nmol/L5. 
Patients with suspected AI (n=25) had lower basalcortisol levels than those with pseudo-CS or CD (Table 1). At 
the end of the diagnostic work-up, AI was ruled out in 14/25 (56%) patients; a pituitary and a hypothalamic 
origin was confirmed in 5 and 6 patients, respectively. Considering a follow-up of at least 12 months, all 
patients without AI did not show signs or symptoms of acute adrenal crisis, and glucocorticoid replacement 
treatment was not introduced. 
Basalcortisol levels and AUCcortisol after hCRHtest were lower in patients with AI than in those with an adequate 
HPA axis function (as reported in Supplementary table 1). Basalcortisol >215 nmol/L and AUCcortisol >44767 
proved sufficiently accurate in ruling out AI (with a SE 85.7%, SP 72.7%, AUC 0.844, and a SE 85.7%, SP 
63.6%, AUC 0.734, respectively).  
Basal and hCRH-stimulated ACTH and cortisol levels were of no further help in diagnosing AI, and their 
levels were similar in patients with a hypothalamic as opposed to a pituitary etiology of AI (as summarized in 
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Supplementary figure 2). Considering ACTH or cortisol levels after hCRH injection, the curve of patients with 
AI of pituitary origin had a different profile (more reduced and blunted) from those with AI of hypothalamic 
origin. Further studies on larger populations are needed to ascertain whether hCRHtest can differentiate central 
AI. 
An accurate diagnosis of central AI is essential in patients with hypothalamic or pituitary injury. Corticotropin 
testing can detect only a reduced adrenal response to ACTH1. The insulin tolerance test is unable to distinguish 
central AI because CRH only stimulates the secretion of ACTH at pituitary level. While the role of the hCRHtest 
in patients with suspected hypercortisolism is well established, its diagnostic accuracy in AI, or in 
differentiating hypothalamic from pituitary HPA axis impairment, is still debated7. In our study, we did not 
perform hCRHtest in controls, and we can only consider subjects without AI as adrenal sufficient. Basal cortisol 
levels and hCRH-stimulated AUCcortisol could suggest AI (both SE >80%), but their role in excluding subjects 
with a normal HPA axis was limited (SP ≈70%), as previously reported4.  
In our series, the hCRHtest was unable to differentiate between a hypothalamic and a pituitary origin of AI, for 
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Supplementary table 1: Patients’ basal and post-hCRH characteristics. Adrenal sufficiency: patients with a 
normal hypothalamic pituitary adrenal axis. AI: adrenal insufficiency; AUC: area under the curve. a: p<0.05 










ACTH morning (pg/mL)  21.5 (4.2) 13.7 (2.3) 15 (3.9) 12 (2) 
BasalACTH (pg/mL) hCRHtest 30.1 (9.5) 12 (1.8) 11.8 (2.4) 13.2 (3.2) 
Basalcortisol (nmol/L) hCRHtest 311 (31.6) 160 (30.4) a 147.5 (62.2) 155.2 (28.1) 
PeakACTH (pg/mL) hCRHtest 85.2 (27.4) 48 (10.2) 36.2 (12.9) 65.8 (15.7) 
Peakcortisol (nmol/L) hCRHtest 530.7 (69.4) 343 (66.3) 277 (136.2) 402.4 (60) 
∆%ACTH  2.14 (0.46) 3.4 (0.97) 2.31 (1.25) 4.76 (1.61) 
∆%cortisol 0.84 (0.2) 1.1 (0.31) 0.52 (0.28) 1.8 (0.47) 
AUCACTH 6371 (1577) 3861 (687) 3171 (855) 4983 (1094) 
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Supplementary figure 2: ACTH  and cortisol curve during hCRHtest in patients with normal adrenal function, 
adrenal insufficiency (AI), pituitary AI and hypothalamic AI. 
 
 
